Ozempic, Wegovy get new rivals as Kenya approves seven Semaglutide drugs

Kenya's drug regulator has approved seven semaglutide products, including generics, expanding treatment options for type 2 diabetes and weight management amid rising obesity and diabetes cases. The approvals include different indications restricting interchangeability, and the regulator warns against off-label use and black market purchases.

This Wire brief sits within Fusion42's coverage of Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.